KOWA CO. LTD. 7807
TSE · Japan · Health Technology
¥873.00-2.00 (-0.23%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Press Release Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment NCX 470 New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) by exclusive licensee Kowa Company, Ltd. (Kowa) for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension€3 million milestone payment due to Nicox, with a further milestone payment due upon approvalSubmission based on posit
KOWA–Amogy MoU Signing Amogy and KOWA sign memorandum of understanding (MoU) to provide ammonia cracking-based hydrogen supply in Japan. NEW YORK AND TOKYO, June 16, 2026 (GLOBE NEWSWIRE) -- Amogy, a provider of mature, scalable, and efficient ammonia-to-hydrogen and ammonia-to-power solutions, and KOWA Company, Ltd. (KOWA) today announced a partnership to bring ammonia cracking-based hydrogen supply solutions in Japan, following the signing of a Memorandum of Understanding (MoU) between the two
Kowa Company, Ltd. (Headquarters: Nagoya, Aichi Prefecture, Japan), today announced an upcoming presentation of non-clinical data for K‑679, its novel antibody drug-loaded unimicelle conjugate (ADUC) with unprecedented drug loading capacity. The compound, developed using Kowa's proprietary micelle technology, has demonstrated tumor-selective pharmacokinetics, extensive intratumoral distribution, and superior efficacy in EGFR-expressing solid tumors compared to conventional antibody drug conjugat
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.